Gateway Investment Advisers LLC increased its stake in IQVIA Holdings Inc. (NYSE:IQV – Get Rating) by 8.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,107 shares of the medical research company's stock after buying an additional 85 shares during the quarter. Gateway Investment Advisers LLC's holdings in IQVIA were worth $240,000 as of its most recent SEC filing.
Several other large investors also recently made changes to their positions in IQV. Norges Bank acquired a new stake in shares of IQVIA in the 4th quarter valued at approximately $509,423,000. Parnassus Investments LLC bought a new stake in IQVIA in the 1st quarter valued at $175,759,000. 1832 Asset Management L.P. raised its stake in IQVIA by 1,061.8% in the 4th quarter. 1832 Asset Management L.P. now owns 598,612 shares of the medical research company's stock valued at $169,094,000 after acquiring an additional 547,089 shares during the period. Boston Partners raised its stake in IQVIA by 10,521.5% in the 1st quarter. Boston Partners now owns 537,343 shares of the medical research company's stock valued at $124,262,000 after acquiring an additional 532,284 shares during the period. Finally, State Street Corp raised its stake in IQVIA by 4.6% in the 1st quarter. State Street Corp now owns 8,306,345 shares of the medical research company's stock valued at $1,920,510,000 after acquiring an additional 362,541 shares during the period. Institutional investors and hedge funds own 86.77% of the company's stock.
Get IQVIA alerts:Analyst Ratings Changes
A number of equities research analysts recently weighed in on IQV shares. Morgan Stanley increased their price target on IQVIA from $255.00 to $260.00 and gave the company an "overweight" rating in a research note on Friday, July 22nd. SVB Leerink started coverage on IQVIA in a research report on Friday, July 15th. They set an "outperform" rating and a $256.00 price objective on the stock. Credit Suisse Group started coverage on IQVIA in a research report on Wednesday, August 24th. They set an "outperform" rating and a $300.00 price objective on the stock. StockNews.com cut IQVIA from a "buy" rating to a "hold" rating in a research report on Wednesday. Finally, Barclays lowered their price objective on IQVIA from $255.00 to $235.00 and set an "overweight" rating on the stock in a research report on Monday, September 12th. Two research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. According to MarketBeat, IQVIA currently has a consensus rating of "Moderate Buy" and an average price target of $275.00.
IQVIA Stock Performance
NYSE:IQV opened at $189.43 on Friday. The stock's 50-day simple moving average is $223.04 and its 200 day simple moving average is $219.92. The firm has a market capitalization of $35.33 billion, a PE ratio of 31.62, a price-to-earnings-growth ratio of 1.74 and a beta of 1.34. The company has a quick ratio of 0.96, a current ratio of 0.96 and a debt-to-equity ratio of 2.36. IQVIA Holdings Inc. has a twelve month low of $186.24 and a twelve month high of $285.61.IQVIA (NYSE:IQV – Get Rating) last released its quarterly earnings data on Thursday, July 21st. The medical research company reported $2.44 earnings per share for the quarter, beating the consensus estimate of $2.22 by $0.22. The business had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.49 billion. IQVIA had a return on equity of 30.21% and a net margin of 8.21%. IQVIA's revenue was up 3.0% compared to the same quarter last year. During the same period last year, the firm posted $1.94 earnings per share. On average, analysts anticipate that IQVIA Holdings Inc. will post 9.4 EPS for the current fiscal year.
IQVIA Company Profile
(Get Rating)
IQVIA Holdings Inc provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Read More
- Get a free copy of the StockNews.com research report on IQVIA (IQV)
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- 2 Semiconductor Stocks To Watch For Reversals
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.